查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938816

慢性特發性便秘治療市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、給藥途徑、通路、地區及競爭格局分類，2021-2031年）

Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球慢性特發性便秘治療市場預計將從 2025 年的 115.3 億美元成長到 2031 年的 164.6 億美元，複合年成長率為 6.11%。

本板塊涵蓋專門針對無法明確生理或系統性病因的持續性便秘病例而研發的藥物和處方治療方案。推動該板塊成長的主要因素包括功能性胃腸疾病盛行率的上升、全球人口老化導致結腸動力減弱，以及醫療保健領域對慢性病管理投入的增加。此外，久坐生活方式的興起和飲食習慣的改變也擴大了就醫人群。國際胃腸疾病基金會指出，到2024年，全球約有六分之一到七分之一的人口將受到便秘的困擾，凸顯了有效治療方案的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 115.3億美元
市場規模：2031年 164.6億美元
複合年成長率：2026-2031年 6.11%
成長最快的細分市場 腸外
最大的市場 北美洲

儘管有這些正面因素，市場仍面臨一項重大挑戰：消費者普遍依賴非處方藥和膳食補充劑。許多出現症狀的患者選擇使用價格低廉且易於獲得的替代品進行自我治療，而不是尋求專業醫療建議，這種趨勢減緩了向更先進的處方治療方案的過渡。這一趨勢顯著限制了專門用於治療慢性特發性便秘的藥物的目標患者群體，並阻礙了該細分市場的收入成長。

市場促進因素

慢性特發性便秘在全球日益普遍，這主要受久坐少動的生活方式和飲食習慣改變的影響，也是推動市場擴張的主要因素。加速的都市化和體力活動減少導致功能性腸道疾病的盛行率上升，使得尋求醫療服務的患者人數不斷增加。這一趨勢導致患者從非處方藥轉向處方藥，從而對成熟治療方法產生了穩定的需求。近期產業指標也反映了這一趨勢，Ironwood Pharmaceuticals於2025年12月發布的2025年第三季財務報告顯示，LINZESS的總處方需求年增12%。

此外，藥理學創新和具有全新作用機制的治療方法的引入推動了收入成長，這些療法提高了疑難病例的療效。產業正朝著下一代藥物發展，其中鈉氫交換器3 (NHE3) 抑制劑和鳥苷酸環化酶C促效劑的市場佔有率正在迅速成長。這種趨勢在財務表現中顯而易見。 Alderix公司在2025年10月發布的第三季財報中指出，由於處方醫生對該藥物的接受度提高，其創新藥物IBSRELA的淨銷售額達到7,820萬美元。此外，Ironwood Pharmaceuticals公司在2025年2月發布的報告中指出，LINZESS在美國的獨立淨銷售額在2024年達到9.163億美元，凸顯了這些專科療法的巨大商業性價值。

市場挑戰

全球慢性特發性便秘治療市場面臨的一大障礙是患者對膳食補充劑和非處方瀉藥的過度依賴。這種根深蒂固的自我用藥習慣嚴重阻礙了處方藥的普及，因為患者通常會在尋求專業建議之前先選擇價格低廉且易於取得的非處方產品。因此，慢性特發性便秘的正式診斷常常被延誤或忽略，導致相當一部分潛在患者無法獲得能夠創造市場利益的、先進的高價值處方藥治療。

這種不願介入的態度限制了專科藥物的普及，即便嚴重的症狀需要專科治療。當患者認為非處方藥就足夠時，無論其長期療效如何，藥廠在取得市場佔有率方面都面臨挑戰。例如，美國胃腸病學會2024年的一項調查發現，95%的便秘患者表示排便時需要用力，這表明儘管嘗試自我護理，症狀負擔仍然很重。這種症狀嚴重程度與持續依賴非處方藥之間的脫節抑制了處方藥療法的普及，直接阻礙了市場的成長。

市場趨勢

製藥公司正不斷擴大適應症範圍，將兒童族群納入其中，拓寬了慢性特發性便秘治療的潛在患者群。製造商正尋求監管部門批准，將已上市的鳥苷酸環化酶C促效劑的使用範圍擴展至青少年和兒童，而這一人群以往只能使用滲透性瀉藥和仿單標示外核准。此舉旨在滿足兒童功能性腸道疾病領域的重要未滿足需求，同時展現出對低齡患者的安全性。根據《製藥技術》雜誌2025年11月報道，美國食品藥物管理局（FDA）已核准Linzess用於治療7歲及以上以便秘大腸激躁症兒童，有效拓展了該藥物的市場覆蓋範圍，使其不再局限於傳統的成人適應症。

同時，隨著非專利藥促動力藥的上市，競爭格局正在重塑，成本障礙也隨之降低。隨著專利到期，生物等效替代藥物已進入市場，擴大了先前因品牌藥高昂自付費用而受限的患者的治療機會。這些低成本替代藥物的出現，使得醫療服務提供者能夠更頻繁地開立專科促動力藥，從而推動了該類藥物處方量的成長。例如，ANI製藥公司宣布將於2025年1月在美國推出首個學名藥Motegrity（普魯卡必利），目標市場為年銷售額估計為1.68億美元的品牌藥市場。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球慢性特發性便秘治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類別（容積性瀉藥、潤膚劑、刺激性瀉藥、滲透性瀉藥）
    • 給藥途徑（口服、注射）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美慢性特發性便秘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲慢性特發性便秘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區慢性特發性便秘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東與非洲慢性特發性便秘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲慢性特發性便秘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球慢性特發性便秘治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GSK PLC
  • Astellas Pharma Inc
  • Synergy Pharmaceuticals Inc.
  • Bayer AG
  • Allergan PLC
  • Sanofi SA
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • Zydus Lifesciences Ltd
  • Boehringer Ingelheim GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18866

The Global Chronic Idiopathic Constipation Therapeutic Market is projected to expand from USD 11.53 Billion in 2025 to USD 16.46 Billion by 2031, reflecting a compound annual growth rate of 6.11%. This sector encompasses pharmaceutical agents and prescription treatments specifically developed for persistent constipation cases lacking a distinct physiological or systemic origin. Growth is primarily driven by the increasing prevalence of functional gastrointestinal disorders, an aging global population prone to reduced colonic motility, and rising healthcare investments in chronic disease management. Additionally, shifts toward sedentary lifestyles and dietary changes are enlarging the patient base needing medical attention. The International Foundation for Gastrointestinal Disorders noted in 2024 that constipation affects approximately 1 in every 6 to 7 individuals globally, highlighting the significant need for effective therapeutic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.53 Billion
Market Size 2031USD 16.46 Billion
CAGR 2026-20316.11%
Fastest Growing SegmentParenteral
Largest MarketNorth America

Despite these positive indicators, the market confronts a major obstacle regarding widespread consumer dependence on over-the-counter laxatives and dietary supplements. A substantial number of individuals experiencing symptoms opt for self-medication with affordable, accessible alternatives rather than pursuing professional medical diagnoses, a behavior that postpones the shift to advanced prescription therapies. This tendency significantly constrains the addressable audience for specialized chronic idiopathic constipation therapeutics and hinders broader revenue growth within the sector.

Market Driver

The rising global incidence of chronic idiopathic constipation, fueled by sedentary lifestyles and dietary modifications, serves as a primary engine for market expansion. As urbanization accelerates and physical activity diminishes, the prevalence of functional bowel disorders has increased, resulting in a larger patient population requiring medical care. This dynamic has led to a noticeable shift of patients moving from over-the-counter remedies to prescription-grade treatments, creating consistent demand for established therapies. Recent industry metrics reflect this trend; according to Ironwood Pharmaceuticals' Third Quarter 2025 Results released in December 2025, total prescription demand for LINZESS rose by 12% compared to the prior year.

Revenue growth is further stimulated by pharmacological innovations and the introduction of therapies with novel mechanisms of action, which offer enhanced efficacy for difficult-to-treat cases. The sector is evolving toward next-generation agents, including sodium-hydrogen exchanger 3 (NHE3) inhibitors and guanylate cyclase-C agonists, which are quickly capturing market share. This adoption is evidenced by financial performance; Ardelyx reported in its October 2025 Third Quarter Financial Results that net product sales for the novel agent IBSRELA hit $78.2 million due to increased prescriber uptake. Additionally, the significant commercial value of these specialized treatments is highlighted by Ironwood Pharmaceuticals' February 2025 report, which noted that full-year 2024 U.S. net sales for LINZESS alone reached $916.3 million.

Market Challenge

A major hurdle inhibiting the Global Chronic Idiopathic Constipation Therapeutic Market is the extensive patient reliance on dietary supplements and over-the-counter laxatives. This deeply rooted habit of self-medication establishes a significant barrier to prescription therapy adoption, as individuals usually utilize affordable, readily available retail products before seeking professional advice. Consequently, formal diagnoses of Chronic Idiopathic Constipation are often delayed or overlooked, effectively preventing a substantial segment of the potential patient base from accessing advanced, higher-value prescription treatments that generate market revenue.

This hesitation to pursue medical intervention limits the reach of specialized therapeutics, even when severe symptoms warrant professional care. Pharmaceutical manufacturers face difficulties in gaining market share when patients view non-prescription alternatives as sufficient, regardless of their actual long-term effectiveness. For instance, the American College of Gastroenterology reported in a 2024 real-world survey that 95% of patients with constipation-related issues experienced straining during bowel movements, indicating a heavy symptom burden that remains despite self-care attempts. This gap between high symptom severity and persistent dependence on retail solutions curtails the uptake of prescription therapies, directly impeding the market's financial growth.

Market Trends

Pharmaceutical companies are increasingly expanding label indications to include pediatric populations, thereby widening the addressable patient base for chronic idiopathic constipation therapeutics. Manufacturers are securing regulatory approvals to extend the use of established guanylate cyclase-C agonists to adolescents and children, a group previously restricted to osmotic laxatives or off-label treatments. This strategic development targets a significant unmet need within pediatric functional bowel disorders while validating safety profiles for younger users. As reported by Pharmaceutical Technology in November 2025, the FDA approved Linzess for children aged seven and older with irritable bowel syndrome with constipation, effectively expanding the drug's market reach beyond its original adult indications.

Concurrently, the competitive landscape is being reshaped by the introduction of generic prokinetic agents, which are lowering cost barriers. The patent expiration for serotonin-4 receptor agonists has prompted the release of bioequivalent alternatives, making treatments more accessible to patients limited by the high out-of-pocket expenses associated with branded drugs. This availability of lower-cost options enables healthcare providers to prescribe specialized prokinetics more frequently, boosting volume growth in this segment. For example, ANI Pharmaceuticals announced in January 2025 the launch of the first U.S. generic version of Motegrity (prucalopride), targeting a branded market estimated at $168 million annually.

Key Market Players

  • GSK PLC
  • Astellas Pharma Inc
  • Synergy Pharmaceuticals Inc.
  • Bayer AG
  • Allergan PLC
  • Sanofi SA
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • Zydus Lifesciences Ltd
  • Boehringer Ingelheim GmbH

Report Scope

In this report, the Global Chronic Idiopathic Constipation Therapeutic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Idiopathic Constipation Therapeutic Market, By Drug Class

  • Bulk-Forming Agents
  • Emollients
  • Laxatives
  • Osmotic Agents

Chronic Idiopathic Constipation Therapeutic Market, By Route of Administration

  • Oral
  • Parenteral

Chronic Idiopathic Constipation Therapeutic Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chronic Idiopathic Constipation Therapeutic Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Idiopathic Constipation Therapeutic Market.

Available Customizations:

Global Chronic Idiopathic Constipation Therapeutic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Bulk-Forming Agents, Emollients, Laxatives, Osmotic Agents)
    • 5.2.2. By Route of Administration (Oral, Parenteral)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Idiopathic Constipation Therapeutic Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GSK PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Astellas Pharma Inc
  • 15.3. Synergy Pharmaceuticals Inc.
  • 15.4. Bayer AG
  • 15.5. Allergan PLC
  • 15.6. Sanofi SA
  • 15.7. Pfizer Inc
  • 15.8. Takeda Pharmaceutical Co Ltd
  • 15.9. Zydus Lifesciences Ltd
  • 15.10. Boehringer Ingelheim GmbH

16. Strategic Recommendations

17. About Us & Disclaimer